共 14 条
[1]
Ferrara F.(2008)Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma Clin Drug Invest 28 55-65
[2]
Ravasio R.(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379-91
[3]
Pfreundschuh M.(2002)Pitfalls associated with commonly used methods for pharmacoeconomic analyses Pharmacotherapy 22 35s-8s
[4]
Trumper L.(2006)Managing oncology costs Am J Manag Care 12 3-16
[5]
Osterborg A.(2001)Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients Oncologist 6 441-5
[6]
Klepser D.(1992)Guidelines for performing a pharmacoeconomic analysis Am J Hosp Pharm 49 1741-7
[7]
Reeder C(undefined)undefined undefined undefined undefined-undefined
[8]
Gordon D(undefined)undefined undefined undefined undefined-undefined
[9]
Calhoun E.(undefined)undefined undefined undefined undefined-undefined
[10]
Chang C.H.(undefined)undefined undefined undefined undefined-undefined